panitumumab
- Generic Name
- panitumumab
- Brand Names
- Vectibix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 339177-26-3
- Unique Ingredient Identifier
- 6A901E312A
- Background
Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.
Panitumumab was granted FDA approval on 27 September 2006.
- Indication
美国FDA批准：用于野生型KRAS(外显子2)转移性结直肠癌(mCRC)患者的一线治疗。
- Associated Conditions
- Metastatic Colorectal Cancer (CRC)
- Associated Therapies
- -
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
- Conditions
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 112
- Registration Number
- NCT05845450
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Lombardia/MI, Italy
(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-02-28
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Michael Topf
- Target Recruit Count
- 60
- Registration Number
- NCT05747625
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 90
- Registration Number
- NCT05694936
- Locations
- 🇦🇺
Eben-Marie Garzina, Ballarat Central, Victoria, Australia
🇦🇺Southern Adelaide Local Health Network Incorporated, Bedford Park, South Australia, Australia
🇦🇺Austin Health, Melbourne, Victoria, Australia
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 105
- Registration Number
- NCT05638295
- Locations
- 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles, California, United States
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Conditions
- Metastatic HER2-Negative Breast CarcinomaLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmRecurrent Endometrial CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Malignant Female Reproductive System NeoplasmRecurrent Ovarian CarcinomaUnresectable HER2-Negative Breast CarcinomaUnresectable Malignant Solid NeoplasmAdvanced Malignant Solid Neoplasm
- Interventions
- Procedure: BiopsyDrug: AlpelisibDrug: BinimetinibProcedure: Bone Marrow AspirationProcedure: Biospecimen CollectionProcedure: Bone ScanDrug: IpatasertibProcedure: Computed TomographyProcedure: EchocardiographyDrug: Nilotinib Hydrochloride MonohydrateBiological: PanitumumabProcedure: Magnetic Resonance ImagingDrug: PaclitaxelDrug: SotorasibDrug: OlaparibDrug: FluorouracilProcedure: Mutation Carrier ScreeningDrug: Neratinib MaleateDrug: LeucovorinDrug: FulvestrantProcedure: Positron Emission TomographyDrug: PalbociclibProcedure: Multigated Acquisition ScanDrug: Selumetinib SulfateDrug: Oxaliplatin
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2900
- Registration Number
- NCT05564377
- Locations
- 🇺🇸
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea, Michigan, United States
🇺🇸Corewell Health Dearborn Hospital, Dearborn, Michigan, United States
🇺🇸Corewell Health Farmington Hills Hospital, Farmington Hills, Michigan, United States
Study Evaluating Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Andrei Iagaru
- Target Recruit Count
- 60
- Registration Number
- NCT05423197
- Locations
- 🇺🇸
Stanford Cancer Institute, San Francisco, California, United States
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
- Conditions
- Interventions
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 160
- Registration Number
- NCT05198934
- Locations
- 🇯🇵
Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan
🇺🇸Kelsey Research Foundation, Houston, Texas, United States
🇺🇸Northwest Georgia Oncology Centers PC, Marietta, Georgia, United States
Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Breast Inflammatory CarcinomaInvasive Breast CarcinomaPrognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05177796
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab
- Conditions
- Interventions
- First Posted Date
- 2021-11-16
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Anup Kasi
- Target Recruit Count
- 50
- Registration Number
- NCT05121038
- Locations
- 🇺🇸
The University of Kansas Cancer Center (KUCC), Fairway, Kansas, United States
🇺🇸The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas, United States
🇺🇸The University of Kansas Medical Center, North Kansas City, Missouri, United States
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05084859
- Locations
- 🇺🇸
Duke Cancer Institute (DCI) - Duke Cancer Center, Durham, North Carolina, United States
🇺🇸UT Health San Antonio - Mays Cancer Center - Institute for Drug Development, San Antonio, Texas, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.